Compare GORO & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GORO | HELP |
|---|---|---|
| Founded | 1998 | N/A |
| Country | United States | Canada |
| Employees | N/A | 50 |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 207.5M | 233.0M |
| IPO Year | 2010 | N/A |
| Metric | GORO | HELP |
|---|---|---|
| Price | $1.01 | $7.27 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $1.63 | ★ $51.50 |
| AVG Volume (30 Days) | ★ 2.7M | 1.5M |
| Earning Date | 05-07-2026 | 07-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 91.80 | N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $99,759,000.00 | N/A |
| Revenue This Year | $25.99 | N/A |
| Revenue Next Year | $5.78 | N/A |
| P/E Ratio | $31.26 | ★ N/A |
| Revenue Growth | ★ 51.78 | N/A |
| 52 Week Low | $0.43 | $3.76 |
| 52 Week High | $1.87 | $8.55 |
| Indicator | GORO | HELP |
|---|---|---|
| Relative Strength Index (RSI) | 30.31 | 71.00 |
| Support Level | $0.80 | $5.77 |
| Resistance Level | $1.02 | $8.55 |
| Average True Range (ATR) | 0.11 | 0.47 |
| MACD | -0.03 | 0.07 |
| Stochastic Oscillator | 10.32 | 91.81 |
Gold Resource Corp is a producer of metal concentrates that contain gold, silver, copper, lead, and zinc in Oaxaca, Mexico. . It targets low capital expenditure projects with the potential for generating high returns on capital. The company's two pipeline projects are; Don David Gold at Oaxaca, Mexico, and Back Forty at Michigan, United States of America. The Company has two reporting segments, based on geographic regions. Oaxaca, Mexico represents the Companies only operating segment with a production stage property. The Companies other reporting segment is Michigan, U.S.A., with an exploration stage property.
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.